Literature DB >> 22080977

Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.

P Hemachandra Reddy1, Ulziibat P Shirendeb.   

Abstract

Huntington's disease (HD) is a progressive, fatal neurodegenerative disease caused by expanded polyglutamine repeats in the HD gene. HD is characterized by chorea, seizures, involuntary movements, dystonia, cognitive decline, intellectual impairment and emotional disturbances. Research into mutant huntingtin (Htt) and mitochondria has found that mutant Htt interacts with the mitochondrial protein dynamin-related protein 1 (Drp1), enhances GTPase Drp1 enzymatic activity, and causes excessive mitochondrial fragmentation and abnormal distribution, leading to defective axonal transport of mitochondria and selective synaptic degeneration. This article summarizes latest developments in HD research and focuses on the role of abnormal mitochondrial dynamics and defective axonal transport in HD neurons. This article also discusses the therapeutic strategies that decrease mitochondrial fragmentation and neuronal damage in HD.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22080977      PMCID: PMC3249480          DOI: 10.1016/j.bbadis.2011.10.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  156 in total

Review 1.  Presynaptic dysfunction in Huntington's disease.

Authors:  José L Rozas; Leonardo Gómez-Sánchez; Cristina Tomás-Zapico; José J Lucas; Rafael Fernández-Chacón
Journal:  Biochem Soc Trans       Date:  2010-04       Impact factor: 5.407

Review 2.  RNAi medicine for the brain: progresses and challenges.

Authors:  Ryan L Boudreau; Edgardo Rodríguez-Lebrón; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2011-03-31       Impact factor: 6.150

3.  Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

Authors:  B Stephens; A J Mueller; A F Shering; S H Hood; P Taggart; G W Arbuthnott; J E Bell; L Kilford; A E Kingsbury; S E Daniel; C A Ingham
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

4.  The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

Authors:  Erica Rockabrand; Natalia Slepko; Antonello Pantalone; Vidya N Nukala; Aleksey Kazantsev; J Lawrence Marsh; Patrick G Sullivan; Joan S Steffan; Stefano L Sensi; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2006-11-29       Impact factor: 6.150

5.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

6.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Authors:  Ryan L Boudreau; Jodi L McBride; Inês Martins; Shihao Shen; Yi Xing; Barrie J Carter; Beverly L Davidson
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

7.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

8.  ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.

Authors:  Andrea C Klaver; Mary P Coffey; Lynnae M Smith; David A Bennett; John M Finke; Loan Dang; David A Loeffler
Journal:  J Neuroinflammation       Date:  2011-08-09       Impact factor: 8.322

9.  Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity.

Authors:  Wenjun Song; Jin Chen; Alejandra Petrilli; Geraldine Liot; Eva Klinglmayr; Yue Zhou; Patrick Poquiz; Jonathan Tjong; Mahmoud A Pouladi; Michael R Hayden; Eliezer Masliah; Mark Ellisman; Isabelle Rouiller; Robert Schwarzenbacher; Blaise Bossy; Guy Perkins; Ella Bossy-Wetzel
Journal:  Nat Med       Date:  2011-02-20       Impact factor: 53.440

Review 10.  Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's disease.

Authors:  Maria Teresa Tebano; Alberto Martire; Valentina Chiodi; Antonella Ferrante; Patrizia Popoli
Journal:  ScientificWorldJournal       Date:  2010-09-01
View more
  62 in total

Review 1.  Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.

Authors:  J Eva Selfridge; Lezi E; Jianghua Lu; Russell H Swerdlow
Journal:  Neurobiol Dis       Date:  2012-01-10       Impact factor: 5.996

2.  Raft-like microdomains play a key role in mitochondrial impairment in lymphoid cells from patients with Huntington's disease.

Authors:  Laura Ciarlo; Valeria Manganelli; Paola Matarrese; Tina Garofalo; Antonella Tinari; Lucrezia Gambardella; Matteo Marconi; Maria Grasso; Roberta Misasi; Maurizio Sorice; Walter Malorni
Journal:  J Lipid Res       Date:  2012-07-06       Impact factor: 5.922

Review 3.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

4.  Dynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficiencies.

Authors:  Maria Manczak; Hiromi Sesaki; Yusuke Kageyama; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2012-02-23

Review 5.  A role for autophagy in Huntington's disease.

Authors:  Katherine R Croce; Ai Yamamoto
Journal:  Neurobiol Dis       Date:  2018-08-24       Impact factor: 5.996

Review 6.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

Review 7.  The Emerging Roles of Ferroptosis in Huntington's Disease.

Authors:  Yajing Mi; Xingchun Gao; Hao Xu; Yuanyuan Cui; Yuelin Zhang; Xingchun Gou
Journal:  Neuromolecular Med       Date:  2019-01-02       Impact factor: 3.843

8.  Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration.

Authors:  Xing Guo; Marie-Helene Disatnik; Marie Monbureau; Mehrdad Shamloo; Daria Mochly-Rosen; Xin Qi
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

9.  Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons.

Authors:  Jun Tian; Ya-Ping Yan; Rui Zhou; Hui-Fang Lou; Ye Rong; Bao-Rong Zhang
Journal:  Neurosci Bull       Date:  2013-12-21       Impact factor: 5.203

10.  Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.

Authors:  Marta Anglada-Huguet; Xavier Xifró; Albert Giralt; Alfonsa Zamora-Moratalla; Eduardo D Martín; Jordi Alberch
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.